36LBA Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO. Issue 3 (September 2015) - Pauligk, C.; Tannapfel, A.; Meiler, J.; Luley, K.B.; Kopp, H.G.; Homann, N.; Hofheinz, R.D.; Schmalenberg, H.; Probst, S.; Haag, G.M.; Egger, M.; Behringer, D.M.; et al.